Jan Secher proposed as new Member of Elekta Board of Directors
The Nomination Committee of Elekta proposes Jan Secher as new member of Elekta Board of Directors.
Mr. Secher is President and CEO of Ferrostaal AG. He has been Operating Partner of the US private equity fund Apollo in London, and has served as CEO of Clariant AG in Basel and CEO of SICPA in Lausanne. Mr. Secher holds a Masters Degree in Industrial Marketing from University of Linkoping, Sweden. Mr. Secher laid the foundation for his career at the ABB Group, where he worked for over 20 years in Sweden, the USA, Canada, Japan and Switzerland, most recently serving on the Executive Committee of ABB Ltd.
The Nomination Committee proposes to re-elect Akbar Seddigh, Hans Barella, Luciano Cattani, Vera Kallmeyer, Tommy H. Karlsson, Laurent Leksell and Birgitta Stymne Göransson. Carl G. Palmstierna, who has served on the Board since 1993, has declined re-election. Akbar Seddigh is proposed to be re-elected Chairman of the Board.
The full proposal of the Nomination Committee to the AGM 2010 will be posted in the notice of the Annual General Meeting.
The Nomination Committee consists of Åsa Nisell Swedbank, Robur funds, Tove Bångstad, SEB Investment Management, Anders Oscarsson, AMF – Försäkring och Fonder, Laurent Leksell representing his private and companies’ holdings, and Akbar Seddigh, Chairman of the Board.
For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email: email@example.com
Time zone: CET: Central European
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.